Viela Bio’s Uplizna™ Granted FDA Approval As Company’s First Commercial Product Viela Bio’s Uplizna™ (inebilizumab-cdon), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMOSD), was approved by the [….]
Two Frederick, Maryland MedTech Companies Receive FDA 510K Approvals August 13, 2019 Frederick County, Maryland continues to be a vibrant hub for growing bioscience organizations. With its robust life science [….]
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, [….]
Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™ November 20, 2018 Leadiant Biosciences, Inc. formerly known as Sigma-Tau Pharmaceuticals, recently received FDA approval for Revcovi™, which [….]
